Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41989
Title: | Bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter edge-to-edge mitral valve repair in patients with an indication for oral anticoagulation: Results from an all-comers national registry | Authors: | Claeys, Marc J. Aminian, Adel Bartunek, Jozef Bennett, Johan Buysschaert, Ian Claeys, Mathias De Bock , Dina Delodder, Lies Debonnaire, Philippe Dewilde, Willem Ferdinande, Bert Geerinck, Stephanie Goetschalckx, Kaatje Lambrechts, Olivier Lochy, Stijn Paelinck, Bernard P. Rosseel, Liesbeth Vanderheyden, Marc Stroobants, Didier van der Heyden, Jan Verbrugghe, Peter Verheye, Stefan Dubois, Christophe |
Issue Date: | 2023 | Publisher: | WILEY | Source: | CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 103 (2), p. 382-388 | Abstract: | BackgroundEvidence-based recommendations for antithrombotic treatment in patients who have an indication for oral anticoagulation (OAC) after transcatheter edge-to-edge mitral valve repair (TEER) are lacking.AimsTo compare bleeding and thrombotic risk for different antithrombotic regimens post-TEER with MitraClip in an unselected population with the need for OACs.MethodsBleeding and thrombotic complications (stroke and myocardial infarction) up to 3 months after TEER with mitraclip were evaluated in 322 consecutive pts with an indication for OACs. These endpoints were defined by the Mitral Valve Academic Research Consortium criteria and were compared between two antithrombotic regimens: single antithrombotic therapy with OAC (single ATT) and double/triple ATT with a combination of OAC and aspirin and/or clopidogrel (combined ATT).ResultsCollectively, 108 (34%) patients received single ATT, 203 (63%) received double ATT and 11 (3%) received triple ATT. Bleeding events occurred in 67 patients (20.9%), with access site related events being the most frequent cause (37%). Bleeding complications were observed more frequently in the combined ATT group than in the single ATT group: 24% versus 14% [p = 0.03, adjusted RR: 0.55 (0.3-0.98)]. Within the combined group, the bleeding risk was 23% in the double ATT and 45% in the triple ATT group. Thrombotic complications occurred in only three patients (0.9%), and all belonged to the combined ATT group.ConclusionsIn patients with an indication for OACs, withholding of antiplatelet therapy post-TEER with Mitraclip was associated with a 45% reduction in bleeding and without a signal of increased thrombotic risk. | Notes: | Claeys, MJ (corresponding author), Antwerp Univ Hosp, Dept Cardiol, Drie Eikenstr 655, D-2650 Edegem, Belgium. marc.claeys@uantwerpen.be |
Keywords: | antithrombotic therapy;bleeding;MitraClip;mitral valve repair;thrombosis | Document URI: | http://hdl.handle.net/1942/41989 | ISSN: | 1522-1946 | e-ISSN: | 1522-726X | DOI: | 10.1002/ccd.30931 | ISI #: | 001120021500001 | Rights: | 2023 Wiley Periodicals LLC. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Cathet Cardio Intervent - 2023 - Claeys - Bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter.pdf Restricted Access | Published version | 680.17 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.